Clinical Research Directory

Inclusion Criteria: * Age ≥18 years. * Hospitalised for management of a serious gram-positive infection that, in the opinion of the treating clinician, would be treatable with a finite antibiotic duration (e.g., 4-6 weeks). * Receiving alternative effective antibiotic therapy for at least 24 hours and no more than 14 days at screening. * Dalbavancin has been prescribed or is planned to be prescribed by the treating clinician as part of routine clinical care. * Able to provide written informed consent. * Willing and able to participate in study procedures, including follow-up visits and drug monitoring. Exclusion Criteria: * History of severe allergic reaction or hypersensitivity to dalbavancin or any of its components. * Severe renal impairment (eGFR \<30 mL/min/1.73 m²) or currently receiving dialysis. * Decompensated liver disease (Child-Pugh class B or C). * Culture-negative infection. * Any other active infection requiring concurrent antibiotic treatment that could interfere with study outcomes. * Infection caused by a gram-positive organism unlikely to be susceptible to dalbavancin, including Staphylococcus aureus with vancomycin MIC \>2 μg/mL or vanA vancomycin-resistant Enterococcus spp. * Participation in another interventional clinical trial that may confound study outcomes. * Any condition (e.g., severe cognitive impairment or psychiatric illness) that, in the opinion of the investigator, would limit the participant's ability to comply with study procedures or provide informed consent. * Clinical presentation that, in the opinion of the investigator, is unlikely to be suitable for curative or finite antibiotic treatment (e.g., requiring indefinite antibiotic suppression).